Administering adenosine A
View Patent ↗The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A 2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A 2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A 2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinson's disease by administering an adenosine A 2A receptor antagonist singly or together with a dopamine agonist, and/or a COMT inhibitor, and/or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication.
1. A method of reducing or suppressing adverse effects from L-DOPA therapy, comprising administering, to a human patient with Parkinson's Disease, an effective amount of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine or a pharmaceutically acceptable salt thereof,
wherein the patient currently receives said L-DOPA therapy.
2. The method according to claim 1 , wherein the patient suffers from L-DOPA-induced motor complications.
3. The method according to claim 2 , wherein OFF time in motor fluctuations is reduced.
4. The method according to claim 2 , wherein dyskinesias in motor complications are improved.
5. The method according to claim 1 , wherein OFF time in motor fluctuations is reduced.
6. The method according to claim 1 , wherein dyskinesias in motor complications are improved.
7. The method according to claim 1 , wherein the adverse effect comprises ON/OFF fluctuations.
8. The method according to claim 1 , wherein the adverse effect comprises wearing off phenomenon.
9. The method according to claim 1 , wherein the adverse effect comprises dyskinesia.
10. The method according to claim 2 , wherein the adverse effect comprises ON/OFF fluctuations.
11. The method according to claim 2 , wherein the adverse effect comprises wearing off phenomenon.
12. The method according to claim 2 , wherein the adverse effect comprises dyskinesia.